Form 4: QuidelOrtho SVP Werner Kroll Reports Stock Transactions

Werner Kroll, SVP of Research & Development at QuidelOrtho Corp, reports the acquisition and disposition of company stock and restricted stock units on March 28, 2024.

Summary

• On March 28, 2024, Werner Kroll, SVP of Research & Development at QuidelOrtho Corp, reported transactions involving the company's common stock and restricted stock units.
• Kroll acquired 3,811 shares of common stock upon the release of restricted stock units.
• Simultaneously, 1,801 shares were disposed of to cover tax withholding obligations related to the release of these restricted stock units at a price of $47.94 per share.
• Following these transactions, Kroll directly owns 35,781 shares of QuidelOrtho common stock and 7,622 restricted stock units.
• The remaining restricted stock units will vest in equal installments on March 28, 2025, and March 28, 2026.

Sentiment

Score: 5

Explanation: This is a neutral document detailing routine stock transactions by an executive. It doesn't inherently indicate positive or negative sentiment regarding the company's performance.

Future Outlook

The remaining restricted stock units will vest in equal installments on March 28, 2025 and March 28, 2026.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the trading activities of QuidelOrtho's executives. It's a standard practice for publicly traded companies to ensure compliance with SEC regulations.

Comparison to Industry Standards

• Form 4 filings are standard practice across all publicly traded companies in the US, including competitors like Abbott Laboratories, Roche Holding, and Danaher Corporation.
• The reporting requirements and timelines are consistent across the industry, ensuring transparency in insider trading activities.
• Executive compensation packages, including restricted stock units, are common across the diagnostics and medical device industry to align management's interests with shareholder value.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent routine executive compensation and tax obligation fulfillment.
• Shareholders may view the filing as a sign of management's continued investment in the company.

Key Dates